Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 2721


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2721

License Grant
Under the Licensee's original License Agreement with the Licensor for eszopiclone, dated October 1999, the Licensee is obligated to pay a royalty on sales of Lunesta in the United States and, as part of the July 2004 amendment to this Agreement, the Licensee permitted the Licensor, to assign the royalty obligation to a third party in exchange for the right to read and reference the Licensor's regulatory filings related to zopiclone outside of the U.S. for the purpose of development and regulatory registration of eszopiclone outside of the United States. The Licensor has assigned to the Licensee the foreign counterparts to the U.S. patent covering eszopiclone and its therapeutic use.
License Property
Eszopiclone is the active stereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrones, a class of medications called hypnotics. It works by slowing activity in the brain to allow sleep.
Field of Use
Eszopiclone, marketed under the brand-name Lunesta, is a nonbenzodiazepine hypnotic agent (viz., a sedative) used as a treatment for insomnia.

IPSCIO Record ID: 28069

License Grant
Sepracor entered into an agreement with Licensor, under which we exclusively licensed Licensor's preclinical, clinical and post-marketing surveillance data package relating to zopiclone, its isomers and metabolites, to develop, make, use and sell eszopiclone in the United States.
License Property
Licensor assigned all U.S. patent applications relating to (S)-zopiclone to Licensee, and Licensor retained the right under the licensed data package to manufacture (S)-zopiclone in the United States for non-United States markets.  In 2000, we paid a  payment to Licensor upon initiation of Phase III clinical trial of eszopiclone.

Eszopiclone is a nonbenzodiazepine hypnotic which is slightly effective for insomnia

Field of Use
The field of use relates to treating and preventing human disease through the discovery, development and commercialization of innovative pharmaceutical compounds in the healthcare industry.

IPSCIO Record ID: 2518

License Grant
The agreement involves the purchase of rights to the drug Indiplon.  The purchase agreement includes all of the licensee's interest — financial and otherwise.
License Property
Through this transaction, the licensor now controls the indiplon composition of matter patents and other details associated with the transaction.  The drug is nearing the end of Phase III trials.

Indiplon is a nonbenzodiazepine, hypnotic sedative was developed in 2 formulations – an immediate release product for sleep onset and a modified-release version for sleep maintenance.  Indiplon is a unique nonbenzodiazepine agent that acts on a specific site of the GABAA receptor.  It has been shown to bind selectively to the specific subtype of GABAA receptors within the brain believed to be responsible for promoting sleep.

Field of Use
The field of use relates to the medical industry for the treatment of neurological and endocrine-related diseases and disorders.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.